Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Medical marijuana in the US is going to be on shaky ground once FDA approved cannabinoids hit the market. There's probably a 5 year window to capitalize on the current climate but you better have FDA approved drugs if you want to last.
The FDA has taken the position that synthetic drugs are the prefereed route for drug approval. Synthetics are cheaper to manufacture and have higher purity which the FDA requires. Its not so easy to get a pharma partner and pharma is not going to develop a drug that requires the plant. And if the patent is just for a plant extract they better get a synthetic one as well or someone else will come along and blow them out of the water,
They need to get FDA approval to be effective in the US so their IP is protected and so they can sell it cost effectively here.
Synthetics taken orally that are metabolized by the liver are ineffective. The rest are effective. Do you really think non-approved drugs are going to sell when approved drugs are available for consigns like glaucoma?
The FDA sees it differently. Bottom line is OWCP needs to get FDA approval if it really wants to hit it big, create a high barrier to entry and separate itself from the others.
Pretty good article. More of this probably coming.
https://www.insiderfinancial.com/nemus-bioscience-inc-otcmktsnmus-is-capitalized-and-poised-to-run/122467/
As luck would have it, the candidates Nemus and U of M chose as the best are also the cheapest and fastest to get through trials and they already know there won't be side effects to derail them. I think the chemo drug can be fast tracked which won't be very expensive.
Someone who gets it. And when the FDA approved cannabinoids start coming out, medical marijuana is going to struggle to exist. Approved drugs will be cheaper, safer, covered by insurance and doctors won't prescribe anything else. If proven as effective or more effective than non-approved drugs which is likely, there will be no reason for medical marijuana and I doubt the Fed's will let it continue in its current state. Pharma will be putting enormous pressure on Congress as well to clamp down.
it will once they get into clinicals and they release more and more positive news which I expect more of now that they have the funds. I would expect the price to spike within the next several months.
For now, there's no good explanation as to why Nemus has the lowest market cap of every company in this sector.
Whenever Nemus puts out good news, InMed pops 5%. LMAO.
The grow is and was for years of research only. Nemus isn't using the plant for any of their drugs. Nobody is who has any brains.
They're going to fast track their chemo side effect drug since it's so similar to Marinol, glaucoma trials should start in the 4th quarter as rabbit models have had great results and I wouldn't be surprised there's a buyout on their MRSA candidate although I think they feel it has a lot of promise so perhaps a partnership deal. The good news is trials will be cheaper and faster with the indications they're targeting and unlike other developing drugs, they already know there won't be any major side effects to derail this.
There's probably a 6 month lock up but we won't know until they release terms. My confidence level is high that they wouldn't take money from a group that's not committed and who also wouldn't put more money in down the road if needed. Common sense tells me they won't dump because they're not going to be able to dump 60 million shares even if volume spikes to 1 million a day and it will be disclosed which will drive to price down.
Nemus is going to uplist in the next year and either get a development deal or get bought out once they get far enough in trials.
Funny how Nemus has $20 million in cash, numerous patents, a drug candidate that could be approved in 2 years, another in 3-4 and a MRSA candidate that may be the most exciting of all yet the market cap is $8 million. Look at every so called cannabinoid biotech penny stock and their caps and you won't find any of them remotely as solid as Nemus. Nobody has more than $1 million in cash or has the IP Nemus has yet they have caps of $40 million plus. Crazy.
Nemus has turned down money from groups they weren't comfortable with so they didn't take money from just anyone. This group didn't out $20 million in to dump at $2 or while its traded OTC. Dumping 60 million shares wouldn't be easy to do. I'm sure they're committed and Nemus got a long term commitment.
I've got nothing else on them. I'm just pleased they got the deal done and expect a lot of activity the rest of the year. $20 million is a lot of money so this group did months of DD before they put that kind of coin out. As Murphy said, this amount is almost unheard of in these types of circumstances.
From the timeline I saw the CEO had already resigned before they made the final deal but I have no idea if they closed it.
Hey Chico- I'm happy for you that you're a penny stock trader but nobody on this board cares. If you need attention try human interaction. You must take a lot of selfies.
Then you should have no interest in Nemus because this is a long term play and everyone in it knows that. Better luck with your trades.
His butt is hurting from missing the boat on OWCP when it was under a penny, got in at $1.40 and now it's down to .75. Now there's a company with 120 million shares and no cash yet Nemus is the one he thinks is diluted. He also predicted CVSI would pop this year and its dropped in half. He's not exactly clairvoyant.
Welcome aboard eleven inches. So funny as that's been my nickname for years.
The chemo drug will be cheaper because it's basically ready for clinicals and they think they can fast track it. The glaucoma drug will be relatively cheap compared to other drugs because it's easier to test and the results aren't subjective like if they were doing a drug for pain. They still have to make the drug and I think they're nailing down a delivery system. Probably ready by the end of the year.
$20 million gives them enough money to ramp things up and have enough reserves to uplist. About $15 million is needed to uplist. I think they've been holding back or not releasing info that may start coming out to drive the price up by the end of the year where they won't have to do a reverse split. Schneider is going to want a much higher profile now. Nemus has a bunch of smart people on board so I have no doubt this has all been mapped out.
We'll see what happens. One thing I can't explain is why Nemus isn't at least $2 a share. Probably because I own it.
It's just my opinion but there are 2 things at play. Number one, marijuana with the high THC levels now is not as safe as everyone thinks it is. There are people who are predisposed to having significant psychological events like psychosis from continued use. It's a variation in the AKT1 gene and roughly 20% of the population carries that risk. It's not known in the US because of a lack of studies but there have been studies in Europe on it. Google Dr. Christine MIller who has been all over this. That's why Nemus and others steered clear of anything taken orally. I think we're going to see some blowback when moms figure out their kids are getting messed up on it. I'm hearing rumblings of this out of Colorado. It probably won't impact the recreational laws but I think the perception that pot is benign will change in a few years.
As far as medical marijuana is concerned and the 'medicine' that's being made from grows in the legal states, I think they have 3-5 years of making a killing until FDA approved drugs hit the market. Once that happens, I don't see how the medical marijuana guys can survive on a large scale. Pharma will synthetically produce effective FDA approved drugs to target various indications and doctors can prescribe them for anything they see fit. They will replace just about everything the medical marijuana sector is doing and it will be 10 times cheaper and covered by insurance.
On top of that, there will be pressure on the Feds to clean it up because it's the Wild West now. Pharma and the government are not going to allow a free for all of pot drugs being sold that aren't FDA approved to compete with the FDA approved market. Although it's not quite the same thing, the analogy would be similar to pain meds and heroin.
Cheers man. I'm glad you got in.
So Nemus raises $20 million which is unheard of in this space and goes up 6 cents today and InMed goes up 6 cents on no news and drug development 2 years behind Nemus. Lol.
I think a deal with an investment bank is a bit tricky. They seem to be reluctant to invest in a true cannabinoid biotech because the payoff is perceived to be too many years out, GW has been at it for 15 plus years and Zynerba has been at it in some form for 7 years. Once those companies get approved drugs the space should pop. The problem is I think their IP is inferior and the indications they're pursuing are harder to prove effective. If they're not successful, it could hurt the sector. On the flip side, those companies will need to buy out companies that have valuable IP. Nemus purposely targeted indications that aren't subjective, aren't metabolized through the liver and faster through trials. One other thing that's important to note is they already know the drugs are safe. There's no danger of side effects that will derail their candidates which takes away a huge risk factor and they're all convinced they're better than anything else other companies are working on. Biotech has so many risks in drug development but to not have to worry about effectiveness and side effects is huge. It's all about funds here. I think a development deal is more likely but that's a guess.
If they get a development deal, I don't think we'll care about dilution. They've done an excellent job so far in keeping dilution to a minimum which isn't easy with a penny stock. You know InMed and all the others are way more diluted.
I may have already said this but I think medical marijuana will go extinct once the FDA approved drugs hit the market.
I'll be your good friend as long as Nemus hits.
If the timelines shifted, it was because they think they can move the chemo drug along faster than the glaucoma drug. They spent a year and a lot of money being able to show they can produce the chemo drug to FDA standards and they've had to wait to prove it has a shelf life of 2 years before trials can begin. They should be about ready now. They believe that drug is similar enough to Marinol that it can be fast tracked. If so, that's about 2 years away from approval and at a significantly lower cost to get there.
They just announced they're working on the production of their glaucoma drug to meet FDA standards. I think that will be ready by the end of the year. There should be other announcements on it in the interim.
I also think their MRSA drug is a game changer. I've heard for years they think it's a homerun and their recent pr shows additional preliminary scientific proof.
As far as fairness to shareholders and the early ones who invested or who have invested in the private raises, I would say 90% are closely tied to management and long time colleagues and/or friends. They all have money and knowingly went in it for the long haul. They're not interested in $2 per share. They put in looking for $10-$100 per share and are very patient. They only care about moving the candidates along and that the money is used to build legitimate value. I doubt any pay attention to the price and just get updates on the science or when there's a new raise.
I would love to see them have a higher profile but they're not interested in the retail side of it. I'm not sure I agree with that 100% but they're thinking long term and anyone in this stock has to look at it that way. A $7 million market cap is laughable compared to all the others but that only means it's a steal as far as steals go in this risky sector.
The next announcement will be they either did another raise for $1 million plus to move it along if they don't like the proposed partnership deals or a partnership deal. They will hold out for the right deal.
I don't doubt it but do you think Teewinot isn't doing something similar or whoever Zynerba and Insys et. al are using?
I'm sure it would be but as I've said many times, others are doing biosynthesis without chemicals so is it valuable?
Didn't see the bid. Maybe they're hearing things through Roth.
InMed referenced the rat model. I've only seen Nemus reference rabbits for their research which has a high correlation to humans.
That was Brochstein's timeline not fully grasping what's involved. I also think Nemus made their chemo drug their priority because it can be advanced more quickly. Nemus management asked not to be included in the Brochstein stock list and had their reasons which basically means their stock price on the OTC is meaningless to them. They know performance is what will drive the price and not pumping. They don't want to raise capital at pumped levels and piss those investors off when the pump loses its momentum. Look at InMed dropping 30 cents since their pump. Every company doing raises offers downround protection for a year anyway so pumping is rather silly.
The question is has InMed developed a better process or a process that will be valuable because other companies are doing biosynthesis without chemicals.
And the purity levels discussed in the article are different than what the FDA requires and can really on,y be done effectively with synthetic drugs.
There are a couple of companies that have developed them and one of them is in Orange County that Ingram has worked with over the years. I forget the name. Nemus commented on it in one of their releases a year or so back and it may have been in one of the 10-Q's as well where they think implants will be the way their drug and other eye drugs will be administered and they were going to work in conjunction with the company in OC.
I'm not sure why they compared it to Pilocarpine and Timolol other then those seem to be the standard drugs everyone in the sector compares them to. The studies I saw didn't show that Latanoprost to be significantly better than the others and many patients are treated with combos of drops because they lose their effectiveness or work better in combo. Nemus' candidate protects the optic nerve which is critical. Especially in Japan where glaucoma is genetic and usually not caused by IOP. Daily drops will be the thing of the past as implants have been developed and Nemus has already announced that's the method they will eventually use.
Besides the 2 candidates, they also have a MRSA candidate that they've known for years is very effective and they just announced results on it.
They have fewer O/S shares than anyone in the sector and everyone on the OTC needs money and has a going concern.
That's solid analysis. I think InMed has potential but I can't justify a $60 million valuation with 100m outstanding shares while Nemus has a $7 million valuation with 25m outstanding shares. Nemus has numerous patents and is 2-3 years ahead of InMed with their drug candidates. InMed has one pending patent and theire's silence on their alleged pending patent for glaucoma announced 2 years ago. Could it be Nemus beat them to it and they can't get it?
But InMed has something as there are good people involved now and they have been able to raise money.
I hope I didn't talk you out of IMLFF. All I was saying is I don't know what they have and it was being pumped. Where did all the pumpers go now that the price is down to .50 from .72? Their drug candidates are a joke compared to Nemus. Maybe their biosynthesis and bioinformatics are valuable but others are doing something similar contrary to their press releases. The one thing intriguing to me is it seems they have good people involved now.
It wouldn't surprise me if the next announcement is more of the same. That they raise another $2 million at current levels because no development deal could be worked out yet, it wouldn't be my choice but it wouldn't be very dilutive and allows them to move things along until a deal can be made. I think a deal is inevitable it just comes down to when and what terms. Management knows the value and would rather keep doing PIPES rather than give the farm away.
And I know this, no insiders are going to sell until this thing is at least $5 and most likely trading on the Nasdaq or NYSE.
This stock is definitely a risk as all are on this exchange. However, Nemus plays it by the book and quietly raises money and moves their candidates along while others just pump. Nemus has the lowest market cap of every stock in this sector including the ones with known scammers in management. It has the lowest market cap because they do no pumping and there are only 25 million outstanding shares. I wish they would pump but they don't care about anything other than building legitimate value. Nemus clearly has valuable IP and in my opinion, more valuable than every company in the sector including GW, Zynerba and the rest. To have a $7 million valuation is a joke when all the pretenders are at $20 million plus.
The risk with all the companies in this sector trading on the OTC is do they actually have IP and can they raise capital? With Nemus, there is no IP risk, only risk if they can raise capital or not. In other words, this is the least risky company in the cannabinoid sector that's an OTC stock because there is only one risk factor instead of two all the others have.